1.50Open1.95Pre Close1 Volume485 Open Interest230.00Strike Price150.00Turnover37.64%IV9.27%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier17DDays to Expiry1.50Extrinsic Value100Contract SizeAmericanOptions Type-0.1182Delta0.0097Gamma205.58Leverage Ratio-0.1156Theta-0.0131Rho-24.30Eff Leverage0.1072Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet